Results 1 to 10 of about 3,363,784 (294)

The Value of Negative Urinary Dipstick Tests for Haematuria in Patients Undergoing Surveillance for Low-grade Ta Urothelial Cancer: A Two-stage Prospective Clinical Study in 524 Patients

European Urology Open Science
Background and objective: The risk of first recurrence beyond 5 yr for patients with low-grade (LG) Ta non–muscle-invasive bladder cancer (NMIBC) is low enough to consider discontinuing cystoscopic surveillance at that point.
Chandrarajan Premal Shah, Tanya Lord-McKenzie, Antonios Makris, Matthew Trail, Jennifer Gray, Gordon Smith, Paramananthan Mariappan   +6 more
doaj   +1 more source

Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection

Biomarker Research
Background and aims Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA. However, it is not clear which type of
Naheema S. Gordon, Elspeth K. McGuigan, Michaela Ondasova, Jennifer Knight, Laura A. Baxter, Sascha Ott, Robert K. Hastings, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Anshita Goel, Minghao Yu, Roland Arnold, Richard T. Bryan, Douglas G. Ward   +14 more
doaj   +1 more source

Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression

Bladder Cancer
Background The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity.
Jessica L Neil, Naheema S Gordon, Anshita Goel, Ayse N Myumyun, Benjamin Tura, Joep J de Jong, Elai Davicioni, Maurice P Zeegers, Kar Keung Cheng, Nicholas D James, Mario Neou, Roland Arnold, Richard T Bryan, Douglas G Ward   +13 more
doaj   +1 more source

Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation

OncoImmunology, 2019
Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin.
Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R. Parker, Seppo Yla-Herttuala, SUO CTC Bladder Committee, David McConkey, Kimberly S. Schluns, Colin P. Dinney   +11 more
doaj   +1 more source

Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor/Patient Podcast)

Oncology and Therapy
In this plain language podcast, the authors discuss highlights from the American Urological Association (AUA) Annual Meeting 2025. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in ...
Rick Bangs, Roger Li
doaj   +1 more source

Detection of genome-wide methylation changes in bladder cancer by long-read sequencing of urinary DNA

Clinical Epigenetics
Background Non-invasive urine tests for bladder cancer (BC) could reduce dependence on flexible cystoscopy for diagnosis and surveillance. Most recent developments in urine testing are based on targeted detection of genomic and/or epigenomic markers.
Anshita Goel, Benjamin J. Tura, Joanne D. Stockton, Nicholas Tovey, Luke Ames, Andrew D. Beggs, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Richard T. Bryan, Douglas G. Ward, Roland Arnold   +11 more
doaj   +1 more source

Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience

Frontiers in Oncology
IntroductionEnfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a human monoclonal antibody targeting nectin-4.
Evangelia Vlachou, Evangelia Vlachou, Burles Avner Johnson, Burles Avner Johnson, David McConkey, David McConkey, Yuezhou Jing, Andres Matoso, Andres Matoso, Andres Matoso, Andres Matoso, Noah M. Hahn, Noah M. Hahn, Noah M. Hahn, Jean Hoffman-Censits, Jean Hoffman-Censits, Jean Hoffman-Censits   +16 more
doaj   +1 more source

Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)

Bladder Cancer, 2017
Background: Standard treatment for BCG-refractory urothelial cancer is radical cystectomy. Identification of active agents is clearly warranted. Objective: To determine a safe dose of oral everolimus in combination with standard intravesical gemcitabine ...
Guido Dalbagni, Nicole Benfante, Daniel D. Sjoberg, Bernard H. Bochner, S. Machele Donat, Harry W. Herr, Asia S. Mc Coy, Alicia J. Fahrner, Caitlyn Retinger, Jonathan E. Rosenberg, Dean F. Bajorin   +10 more
doaj   +1 more source

High-throughput DNA Sequencing Identifies Novel Variants in Muscle-invasive Bladder Cancer Patients

Bladder Cancer, 2015
Background: Germline mutations in DNA damage signalling and repair genes predispose individuals to cancer. Rare germline variants may also increase cancer risk and be predictive of outcomes following cancer treatments, but require high-throughput ...
Sarah J. Jevons, Angela Green, Gerton Lunter, Christiana Kartsonaki, David Buck, Paolo Piazza, Anne E. Kiltie   +6 more
doaj   +1 more source

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer

Bladder Cancer, 2015
Background: Bacillus Calmette-Guerin (BCG) is the most effective intravesical therapy for non-muscle invasive bladder cancer (NMIBC), but patients can fail or supply shortages can develop. For BCG failures, radical cystectomy is recommended.
Ryan L. Steinberg, Lewis J. Thomas, Michael A. O’Donnell, Kenneth G. Nepple   +3 more
doaj   +1 more source